Aurobindo up over 19%

Today morning, Aurobindo Pharma had an update about its Unit IV, injectable manufacturing formulation facility.

The company stated that the US Food and Drug Administration has determined the inspection classification of the company's general injectable formulation facility at Pashamylaram in Hyderabad as Voluntary Action Indicated (VAI).

This news apart, another good news – it has also got the final approval from the FDA to manufacture and market Fluoxetine Tablets, 10 mg and 20 mg. Fluoxetine tablets are generic version of Eli Lilly’s Prozac® tablets.

The stock is among the top five gainers on the BSE since the news came in. Stock price rose over 19% at Rs.643.40, not too far from its 20% UC of today at Rs.648.65.